Investors
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Letter from the CEO
First steps taken towards late-stage development of vididencel
In the first quarter of 2024, Mendus made significant progress with its lead program vididencel in acute myeloid leukemia (AML).
To read the full letter from the CEO, please click here.
Rights Issue and Directed Issue 2023
You will find all relevant information that are published in connection with the proposed rights issue and directed issue in Mendus on this page.
Update on Vididencel Program – Webcast and On-Site Event
Mendus provided an update on its lead program vididencel on Tuesday, June 27, 2023. The update took place in an online event and, separately, on-site at the company’s headquarters in Stockholm, Sweden.
The replay of the online event is accessible via the link below.
Latest press releases
Events
Contact
Telephone
+46 (0)8 732 8400
info@mendus.com
Head Office
Västra Trädgårdsgatan 15
111 53 Stockholm
Sweden
R&D Offices
Emmy Noetherweg 2K
2333 BK Leiden
The Netherlands
Gothenburg Office
Mendus C/O AstraZeneca BioventureHub
Pepparedsleden 1
431 83 Mölndal
Sweden